Russell Pachynski

Medicine & Life Sciences

1. Prostatic Neoplasms 100%
2. Castration 77%
3. Immunotherapy 70%
4. Neoplasms 60%
5. sipuleucel-T 45%
6. Renal Cell Carcinoma 42%
7. Natural Killer Cells 42%
8. Leukocytes 38%
9. T-Lymphocytes 36%
10. Urinary Bladder Neoplasms 34%
11. Tumor Microenvironment 33%
12. Cell Adhesion Molecule-1 32%
13. Nivolumab 31%
14. Integrins 31%
15. Multiparametric Magnetic Resonance Imaging 30%
16. Anti-Idiotypic Antibodies 27%
17. Survival 26%
18. Antigens 26%
19. Therapeutics 23%
20. Chemotactic Factors 22%
21. TRC105 21%
22. Ipilimumab 21%
23. Melanoma 21%
24. Radiotherapy 21%
25. Proteomics 20%
26. Carcinoma 18%
27. Safety 18%
28. Chemokine CCL21 17%
29. cabozantinib 17%
30. Lymphocytes 17%
31. Axitinib 17%
32. Drug Therapy 17%
33. Central Tolerance 16%
34. pazopanib 16%
35. Neoplasm Metastasis 16%
36. Docetaxel 15%
37. Chemokines 15%
38. Melanoma-Specific Antigens 15%
39. Dendritic Cells 15%
40. Histology 14%
41. Interleukin-7 14%
42. Cell-Free Nucleic Acids 13%
43. tazarotene 13%
44. antineoplaston A10 13%
45. Clinical Trials, Phase I 13%
46. Muscles 13%
47. Radiopharmaceuticals 13%
48. Progression-Free Survival 13%
49. Listeria monocytogenes 12%
50. Watchful Waiting 12%